UNSPSC 51293902: Cinfenine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P26FL0O04P. European Medicines Agency schedules Cinfenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06294MIG. Cinfenine generally arises in the molecular formula C25H27NO. The term CINFENINE is an International Non-Proprietary Name or INN. CINFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule cinfenine under HS 29221980 and SITC 51461. As of Q4 2014, CINFENINE remains the US FDA Preferred Term for this commodity. Cinfenine bears US NLM identifiers UMLS ID C2699221 and NCI Concept Code C78009. SMILES: O(C(c1ccccc1)c1ccccc1)CCN(C/C=C/c1ccccc1)C.

UNSPSC 51293902 Cinfenine, a Commodity code, covers pharmaceutical products and related medical supplies that state and local governments procure for community health, emergency response, and pharmacy benefit programs. Recent solicitations under this code show state and local buyers acquiring naloxone kits, generic multi-source pharmaceuticals, over-the-counter products, and pharmaceutical distribution services to support public health initiatives and employee health plans. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The code reflects a mix of direct pharmaceutical procurement for emergency or community health use and indirect acquisition through pharmacy benefit management and wholesaler relationships that serve broader state and local populations.

Activity appears concentrated in Florida and Minnesota with interstate cooperative purchasing mechanisms. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program serving state agencies and self-insured employee health plans. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. MMCAP designated three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) and required vendors to maintain compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements.